IDWeek
<ѻý class="page-description">A Joint Meeting of IDSA, SHEA, HIVMA, PIDS, and SIDPѻý>Cefixime offers several benefits over penicillin G, researcher says
A vaccine for younger children is urgently needed, researcher says
But is it ready for prime time?
However, questions remain about durability of vaccine protection, expert says
With few exceptions, treatment can be shortened to 7 days, researcher says
Clesrovimab reduced severe disease, hospitalizations in preterm and term healthy infants
"We have no current effective therapies," for mpox, expert warns
New analysis of Moderna's COVE trial looked at best time for boosters
Trials meet all primary aims, poising them to advance toward clinical use
Use of cefepime meanwhile resulted in more neurological dysfunction
One dose proved noninferior to triple-dose regimen in randomized trial
Antiviral protected older at-risk patients, but appeared to increase risk in teens
And second dose after 1 year appeared to add no extra protection
Findings may encourage increased pediatric vaccine uptake, researcher says
-
IDWeek: A Joint Meeting of IDSA, SHEA, HIVMA, PIDS, and SIDP
October 2024
-
CROI: Conference on Retroviruses and Opportunistic Infections
March 2024
-
ASTMH: American Society of Tropical Medicine & Hygiene
October 2022
-
IDWeek Podcast: Podcast from the Joint Meeting of IDSA, SHEA, HIVMA, and PIDS
October 2020